Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AJU-C52 in Essential Hypertension
NCT06416865Phase 3Completed
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine + chlorthalidone + valsartan in essential hypertension (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoint: Mean Sitting Systolic Blood Pressure at 8 weeks. Started Oct 2022; status: completed.
02
Drugs
amlodipine + chlorthalidone + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06416865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416865.